Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Official title

A Phase 1/2 Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of CD19-targeted Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) Therapy in Patients With Relapsed or Refractory B-cell Lymphoma

Overview

This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D). The objective of Phase 2 is to evaluate the safety and efficacy of CD19 CAR-T(known as PL001).

Detailed description

Cluster of differentiation (CD) 19 chimeric antigen receptor T-cell (CAR-T) has been a very promising treatment option for multiple types of B-cell lymphoma. Kymriah® (tisagenlecleucel, Novartis) and Yescarta® (axicabtagene ciloleucel, Gilead) were licensed by the United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) in 2017 to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and High-grade B-cell lymphoma (HGBCL). A third anti-CD19 CAR-T product, Tecartus (brexucabtagene autoleucel, Gilead) was approved by the US FDA for relapsed and refractory mantle cell lymphoma (MCL) in July 2020. In February 2021, another product, Breyanzi® (lisocabtagene maraleucel, Juno Therapeutics, Inc.), was approved by the US FDA for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, Primary mediastinal large B cell lymphoma (PMLBCL), and Gr. 3b FL.

Currently, in Taiwan, no CD19 CAR-T therapies are available commercially.This Phase 1/Phase 2 study will test PL001, a CD19 CAR-T therapy manufactured by Pell Bio-Med Technology Co., Ltd., as a monotherapy for relapsed or refractory B-cell lymphoma. The Phase 1 of the study will be conducted to establish a dose range that is well tolerated by the majority of patients and to provide a safety profile of PL001 in the target patient population. The results of the Phase 1 of the study will recommend the dose selection for the Phase 2 of the study. Phase 2 of the study will assess the efficacy and safety of PL001 in patients with relapsed or refractory B cell lymphoma.

Interventions

• Biological CD19-targeted chimeric antigen receptor T-cell
  Drug: Fludarabine patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3). Drug: Cyclophosphamide patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3). Biological: CD19 CAR-T CD19 CAR-T cells will be administered using as a single dose at

Primary outcome measures

• Phase 1: Dose-limiting toxicities [Time frame: 30 days]
• Phase 2: best overall response (BOR) [Time frame: 12 months]

Secondary outcome measures (6)

• Phase 1 and Phase 2: Treatment-related adverse events [Time frame: 12 months]
• Phase 1 and Phase 2: Best overall response (BOR) [Time frame: 12 months]
• Phase 1 and Phase 2: Median duration of response (mDOR) [Time frame: 12 months]
• Phase 1 and Phase 2: Progression-free survival (PFS) [Time frame: 12 months]
• Phase 1 and Phase 2: Overall survival (OS) [Time frame: 12 months]
• Phase 1 and Phase 2: the health-related quality of life (HRQoL) [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

Screening 1:

• Patient is ≥14 years of age, inclusive, at the time of signing the informed consent.
• Histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMLBCL), large B-cell lymphoma transformed from follicular lymphoma (FL), or grade 3a or 3b FL.
• On-site documentation of CD19 on the dominant population of cancer cells.
• Disease status should meet any one of the below:

• Patients with previous autologous-hematopoietic stem cell transplantation (auto HSCT) have relapsed, progressive, or refractory disease (defined as having not achieved a CR) after transplantation regardless of lines of systemic therapy.
• Patients without previous HSCT have relapsed, progressive, or refractory disease (defined as having not achieved a CR) after at least 2 lines of systemic therapy, including anti-CD20 antibody and anthracycline.
• Have no available effective systemic therapy as judged by the Investigator.
• At least one measurable non-CNS (central nervous system) lesion based on Lugano classification for lymphoma.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• Life expectancy of at least 3 months.
• Patient is male or female.
• A male patient must agree to use a highly effective contraception as detailed in Section 10.4 (Appendix 4) during the treatment period and for at least 2 years after the dose of PL001 and refrain from donating sperm during this period.

Female Patients:

• A female patient is eligible to participate if she is not pregnant (Section 10.4; Appendix 4), not breastfeeding, and at least one of the following conditions applies:

• Not a woman of childbearing potential (WOCBP) as defined in Section 10.4 (Appendix 4).

OR

• A WOCBP who agrees to follow the contraceptive guidance in Section 10.4 (Appendix 4) during the treatment period and for at least 2 years after the dose of PL001 and refrain from donating ova during this period.
• Patient/patient's parent/legal guardian is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Screening 2:

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• CAR-T is successfully manufactured and ready for use, from cells harvested by non mobilized leukapheresis.
• WOCBP who have a negative serum pregnancy test at Screening 2.

Exclusion criteria

Screening 1:

• Chronic lymphocytic leukemia with Richter's transformation.
• Primary CNS lymphoma. (Non-primary CNS lymphoma with CNS involvement is eligible).
• Primary intra-ocular lymphoma.
• Prior CD19 targeted therapy, such as CAR-T, Bi-specific T-cell engagers (BiTE), or monoclonal antibody.
• History of cancers (includes myelodysplastic syndrome) other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease-free without active treatment for at least 3 years.
• History of allogeneic HSCT.
• History of autologous HSCT within 3 months prior to consent.
• Received any investigational product within 4 weeks prior to consent.
• Systemic anticancer therapy within 3 weeks prior to apheresis.
• Long-term use of systemic corticosteroids, defined as daily use >10 mg of prednisolone or equivalent, within 2 weeks prior to leukapheresis.

Exception examples:

• Nasal, ophthalmic, inhaled, intra-articular, and topical steroid preparation.
• Short term systemic steroid for drug, contrast, or blood transfusion allergic reaction management.
• Low dose maintenance steroid therapy for other conditions (e.g., asthma).
• Use of long-acting and short-acting myeloid growth factor within 2 weeks, 5 days prior to leukapheresis, respectively.
• Received anti-thymocyte globulin within 4 weeks prior to consent.
• Intrathecal chemotherapy within 1 week prior to leukapheresis.
• Inadequate major organ functions at Screening, which were defined as any of below:

• absolute neutrophil count (ANC) <500/µL
• Absolute lymphocyte count (ALC) <300/µL, excluding leukemic cells.
• Hemoglobin (Hb) <8.0 g/dL
• Platelet count <75,000/µL without transfusion support within 3 days
• e. Baseline O2 saturation <92% by pulse oximetry at room air
• Significant CNS diseases such as dementia, major stroke, seizure while under antiepileptic drug
• Aspartate aminotransferase (AST) >5 × upper limit of normal (ULN) and alanine aminotransferase (ALT) >5 × ULN, or total bilirubin >2 × ULN (except for constitutional jaundice)
• Serum creatinine > 1.5 × ULN and estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², as calculated by the Cockcroft-Gault formula.
• Significant cardiac disease including but not limited to: left ventricular ejection fraction (LVEF) <50%, QTc(the corrected QT interval) > 480 msec based on Fredericia's formula, clinically significant arrhythmias, history of myocardial infarction or unstable angina within 3 months prior to consent.
• Active hepatitis B virus (HBV) infection defined as detectable HBV DNA (Patients with positive anti-hepatitis B core antibody \[HBcAb\] must consent to regular monitoring of HBV DNA, and anti-HBV prophylaxis with oral anti-viral agent (such as entecavir) is mandatory until End-of-Study visit \[Visit 15\].)
• Active hepatitis C virus (HCV) infection defined as positive anti- HCV antibody plus detectable HCV RNA.
• Positive for human immunodeficiency virus (HIV) or human T-cell lymphotropic virus (HTLV) infection.
• Uncontrolled acute life-threatening bacterial, viral, or fungal infection (e.g., the need for intravenous therapeutic antibiotics, blood culture positive ≤72 hours prior to apheresis).

21\. Any medical conditions which might compromise the patient's safety from leukapheresis, lymphodepletion chemotherapy, or CAR-T therapy and anticipated AEs, according to the Investigator's evaluation.

22.Patients with insufficient leukapheresis cells.

Screening 2:

• Inadequate major organ functions at Screening which were defined as any of below:

• ANC <500/µL
• Hb <8.0 g/dL
• Platelet count <50,000/µL, without transfusion support within 3 days
• Baseline O2 saturation <92% by pulse oximetry on room air
• AST >5 × ULN and ALT>5 × ULN, or total bilirubin >2 × ULN (except for constitutional jaundice)
• Significant CNS diseases such as dementia, major stroke, seizure while under antiepileptic drug
• Serum creatinine > 1.5 × ULN and estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², as calculated by the Cockcroft-Gault formula.
• Long-term use of systemic corticosteroids, defined as daily use >10 mg of prednisolone or equivalent.

Exception examples:

• Nasal, ophthalmic, inhaled, intra-articular, and topical steroid preparation.
• Short term systemic steroid for drug, contrast, or blood transfusion allergic reaction management.
• Low dose maintenance steroid therapy for other conditions (e.g., asthma).
• Use of long-acting and short-acting myeloid growth factor within 12 days, 2 days prior to lymphodepletion therapy, respectively.
• Uncontrolled acute life-threatening bacterial, viral, or fungal infection (e.g. the need for intravenous therapeutic antibiotics, blood culture positive ≤72 hours prior to lymphodepletion).
• Any medical condition which might compromise the patient's safety because of lymphodepletion chemotherapy or CAR-T therapy and anticipated AEs, according to the Investigator's opinion.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Taiwan · 5 centers

• National Taiwan University Hospital — Taipei
• Kaohsiung Medical University Chung-Ho Memorial Hospital — Kaohsiung City
• Chi Mei Medical Center — Tainan
• Taipei Medical University - Taipei Medical University Hospital — Taipei
• Taipei Veterans General Hospital — Taipei

Identifiers

NCT: NCT05326243 · PL001-NHL-201

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗